BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grill HJ. A Role for GLP-1 in Treating Hyperphagia and Obesity. Endocrinology 2020;161:bqaa093. [PMID: 32516384 DOI: 10.1210/endocr/bqaa093] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Rahati S, Qorbani M, Naghavi A, Pishva H. Association and interaction of the MC4R rs17782313 polymorphism with plasma ghrelin, GLP-1, cortisol, food intake and eating behaviors in overweight/obese Iranian adults. BMC Endocr Disord 2022;22:234. [PMID: 36123585 DOI: 10.1186/s12902-022-01129-w] [Reference Citation Analysis]
2 Yadav P, Khurana A, Bhatti JS, Weiskirchen R, Navik U. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. Pharmacol Res 2022;184:106426. [PMID: 36075510 DOI: 10.1016/j.phrs.2022.106426] [Reference Citation Analysis]
3 Avogaro A, de Kreutzenberg SV, Morieri ML, Fadini GP, Del Prato S. Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history. The Lancet Diabetes & Endocrinology 2022. [DOI: 10.1016/s2213-8587(22)00247-9] [Reference Citation Analysis]
4 Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022;7:298. [PMID: 36031641 DOI: 10.1038/s41392-022-01149-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shao Y, Tian J, Yang Y, Hu Y, Zhu Y, Shu Q. Identification of key genes and pathways revealing the central regulatory mechanism of brain-derived glucagon-like peptide-1 on obesity using bioinformatics analysis. Front Neurosci 2022;16:931161. [DOI: 10.3389/fnins.2022.931161] [Reference Citation Analysis]
6 Kiernan R, Persand D, Maddie N, Cai W, Carrillo-Sepulveda MA. Obesity-related vascular dysfunction persists after weight loss and is associated with decreased vascular glucagon-like peptide (GLP-1) receptor in female rats. Am J Physiol Heart Circ Physiol 2022. [PMID: 35749717 DOI: 10.1152/ajpheart.00031.2022] [Reference Citation Analysis]
7 Saari T, Koffert J, Honka H, Kauhanen S, U-Din M, Wierup N, Lindqvist A, Groop L, Virtanen KA, Nuutila P. Obesity-associated Blunted Subcutaneous Adipose Tissue Blood Flow After Meal Improves After Bariatric Surgery. J Clin Endocrinol Metab 2022;107:1930-8. [PMID: 35363252 DOI: 10.1210/clinem/dgac191] [Reference Citation Analysis]
8 Shao J, Li C, Bai L, Ni X, Ge S, Zhang J, Zhao H. Recent evidence in support of traditional chinese medicine to restore normal leptin function in simple obesity. Heliyon 2022;8:e09482. [DOI: 10.1016/j.heliyon.2022.e09482] [Reference Citation Analysis]
9 Rizvi AA, Rizzo M. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes Metab Syndr Obes 2022;15:1023-30. [PMID: 35411165 DOI: 10.2147/DMSO.S351982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Jurkowska K, Szymańska B, Knysz B, Piwowar A. Effect of Combined Antiretroviral Therapy on the Levels of Selected Parameters Reflecting Metabolic and Inflammatory Disturbances in HIV-Infected Patients. JCM 2022;11:1713. [DOI: 10.3390/jcm11061713] [Reference Citation Analysis]
11 Mottl AK, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, Nelson RG, Perreault L, Nicholas SB. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases 2022. [DOI: 10.1053/j.ajkd.2021.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Zhou Y, Chen M, Liu L, Chen Z. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study. Diabetes Metab Syndr Obes 2022;15:155-63. [PMID: 35046686 DOI: 10.2147/DMSO.S348025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci 2022;23:739. [PMID: 35054924 DOI: 10.3390/ijms23020739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
14 Winquist RJ, Gribkoff VK. Cardiovascular effects of GLP-1 receptor agonism. Advances in Pharmacology 2022. [DOI: 10.1016/bs.apha.2022.02.005] [Reference Citation Analysis]
15 Park JW. Asthma Phenotype with Metabolic Dysfunction. Yonsei Med J 2022;63:1-7. [PMID: 34913278 DOI: 10.3349/ymj.2022.63.1.1] [Reference Citation Analysis]
16 Lim J, Ferruzzi MG, Hamaker BR. Dietary starch is weight reducing when distally digested in the small intestine. Carbohydr Polym 2021;273:118599. [PMID: 34560999 DOI: 10.1016/j.carbpol.2021.118599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gallop MR, Wilson VC, Ferrante AW Jr. Post-oral sensing of fat increases food intake and attenuates body weight defense. Cell Rep 2021;37:109845. [PMID: 34686319 DOI: 10.1016/j.celrep.2021.109845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Meyhöfer S, Schmid SM. Neuroendokrine Regulation des menschlichen Energiestoffwechsels. J Klin Endokrinol Stoffw 2021;14:121-125. [DOI: 10.1007/s41969-021-00145-w] [Reference Citation Analysis]
19 Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol 2021. [PMID: 34185884 DOI: 10.1111/bph.15603] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
20 Martin-Moreno PL, Shin HS, Chandraker A. Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation. J Clin Med 2021;10:2497. [PMID: 34198724 DOI: 10.3390/jcm10112497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Holt MK, Rinaman L. The role of nucleus of the solitary tract glucagon-like peptide-1 and prolactin-releasing peptide neurons in stress: anatomy, physiology and cellular interactions. Br J Pharmacol 2021. [PMID: 34050926 DOI: 10.1111/bph.15576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
22 Han Y, Xia G, He Y, He Y, Farias M, Xu Y, Wu Q. A hindbrain dopaminergic neural circuit prevents weight gain by reinforcing food satiation. Sci Adv 2021;7:eabf8719. [PMID: 34039606 DOI: 10.1126/sciadv.abf8719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
23 Williams DL. The diverse effects of brain glucagon-like peptide 1 receptors on ingestive behaviour. Br J Pharmacol 2021. [PMID: 33990944 DOI: 10.1111/bph.15535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
24 Xu W, Dahlke SP, Emery AC, Sung M, Chepurny OG, Holz GG, Eiden LE. Cyclic AMP-dependent activation of ERK via GLP-1 receptor signalling requires the neuroendocrine cell-specific guanine nucleotide exchanger NCS-RapGEF2. J Neuroendocrinol 2021;33:e12974. [PMID: 33960038 DOI: 10.1111/jne.12974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 McCarty MF, Lerner A. Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function. Adv Nutr 2021;12:316-24. [PMID: 33126251 DOI: 10.1093/advances/nmaa139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
26 Montégut L, Lopez-Otin C, Magnan C, Kroemer G. Old Paradoxes and New Opportunities for Appetite Control in Obesity. Trends Endocrinol Metab 2021;32:264-94. [PMID: 33707095 DOI: 10.1016/j.tem.2021.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
27 Li KX, Ji MJ, Sun HJ. An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy. Gene 2021;780:145532. [PMID: 33631244 DOI: 10.1016/j.gene.2021.145532] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
28 Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab 2021;3:258-73. [PMID: 33589843 DOI: 10.1038/s42255-021-00344-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 54.0] [Reference Citation Analysis]
29 Brierley DI, Holt MK, Singh A, de Araujo A, Vergara M, Afaghani MH, Lee SJ, Scott K, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Central and peripheral GLP-1 systems independently and additively suppress eating.. [DOI: 10.1101/2020.08.03.234427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]